nodes	percent_of_prediction	percent_of_DWPC	metapath
Progesterone—NR3C1—Mometasone—systemic scleroderma	0.106	0.296	CbGbCtD
Progesterone—Testolactone—Mometasone—systemic scleroderma	0.0487	0.108	CrCrCtD
Progesterone—Fluoxymesterone—Mometasone—systemic scleroderma	0.0447	0.0996	CrCrCtD
Progesterone—Fludrocortisone—Mometasone—systemic scleroderma	0.0436	0.097	CrCrCtD
Progesterone—Potassium Canrenoate—Prednisone—systemic scleroderma	0.0384	0.0855	CrCrCtD
Progesterone—Prednisolone—Mometasone—systemic scleroderma	0.037	0.0825	CrCrCtD
Progesterone—CYP2C8—Mometasone—systemic scleroderma	0.0364	0.102	CbGbCtD
Progesterone—Hydrocortisone—Mometasone—systemic scleroderma	0.0355	0.0791	CrCrCtD
Progesterone—NR3C1—Prednisone—systemic scleroderma	0.0337	0.0941	CbGbCtD
Progesterone—Danazol—Prednisone—systemic scleroderma	0.0324	0.0722	CrCrCtD
Progesterone—Hydrocortamate—Prednisone—systemic scleroderma	0.0282	0.0628	CrCrCtD
Progesterone—Cortisone acetate—Prednisone—systemic scleroderma	0.0273	0.0609	CrCrCtD
Progesterone—Testolactone—Prednisone—systemic scleroderma	0.0265	0.0591	CrCrCtD
Progesterone—Fludrocortisone—Prednisone—systemic scleroderma	0.0238	0.0529	CrCrCtD
Progesterone—Methyltestosterone—Prednisone—systemic scleroderma	0.0232	0.0516	CrCrCtD
Progesterone—Prednisolone—Prednisone—systemic scleroderma	0.0202	0.0449	CrCrCtD
Progesterone—Hydrocortisone—Prednisone—systemic scleroderma	0.0194	0.0431	CrCrCtD
Progesterone—CYP1A2—Pentoxifylline—systemic scleroderma	0.019	0.0532	CbGbCtD
Progesterone—CYP1A2—Leflunomide—systemic scleroderma	0.0182	0.0507	CbGbCtD
Progesterone—ABCB1—Lisinopril—systemic scleroderma	0.0167	0.0465	CbGbCtD
Progesterone—CYP2C9—Leflunomide—systemic scleroderma	0.0164	0.0457	CbGbCtD
Progesterone—ABCC1—Methotrexate—systemic scleroderma	0.0163	0.0455	CbGbCtD
Progesterone—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0151	0.0421	CbGbCtD
Progesterone—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0145	0.0405	CbGbCtD
Progesterone—ABCB1—Captopril—systemic scleroderma	0.0125	0.0348	CbGbCtD
Progesterone—CYP2D6—Captopril—systemic scleroderma	0.0117	0.0328	CbGbCtD
Progesterone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00981	0.0274	CbGbCtD
Progesterone—CYP2C19—Prednisone—systemic scleroderma	0.00972	0.0271	CbGbCtD
Progesterone—ABCB1—Prednisone—systemic scleroderma	0.00785	0.0219	CbGbCtD
Progesterone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00588	0.0164	CbGbCtD
Progesterone—CYP2C9—cardial valve—systemic scleroderma	0.00535	0.18	CbGeAlD
Progesterone—CYP3A4—Prednisone—systemic scleroderma	0.0047	0.0131	CbGbCtD
Progesterone—ABCB1—Methotrexate—systemic scleroderma	0.00394	0.011	CbGbCtD
Progesterone—PGR—artery—systemic scleroderma	0.0014	0.0473	CbGeAlD
Progesterone—PGR—blood vessel—systemic scleroderma	0.00109	0.0368	CbGeAlD
Progesterone—ESR1—blood vessel—systemic scleroderma	0.000855	0.0288	CbGeAlD
Progesterone—CYP17A1—connective tissue—systemic scleroderma	0.000834	0.0281	CbGeAlD
Progesterone—Danazol—CCL2—systemic scleroderma	0.00073	1	CrCbGaD
Progesterone—SLC10A1—digestive system—systemic scleroderma	0.000692	0.0233	CbGeAlD
Progesterone—ABCB11—digestive system—systemic scleroderma	0.000684	0.023	CbGeAlD
Progesterone—SHBG—connective tissue—systemic scleroderma	0.000622	0.021	CbGeAlD
Progesterone—NR3C2—connective tissue—systemic scleroderma	0.000603	0.0203	CbGeAlD
Progesterone—PGR—connective tissue—systemic scleroderma	0.00056	0.0189	CbGeAlD
Progesterone—NR3C2—smooth muscle tissue—systemic scleroderma	0.000552	0.0186	CbGeAlD
Progesterone—SLC22A2—digestive system—systemic scleroderma	0.000549	0.0185	CbGeAlD
Progesterone—SLC22A3—connective tissue—systemic scleroderma	0.000513	0.0173	CbGeAlD
Progesterone—PGR—smooth muscle tissue—systemic scleroderma	0.000513	0.0173	CbGeAlD
Progesterone—CYP1B1—connective tissue—systemic scleroderma	0.000471	0.0159	CbGeAlD
Progesterone—SLC22A3—smooth muscle tissue—systemic scleroderma	0.000469	0.0158	CbGeAlD
Progesterone—SIGMAR1—smooth muscle tissue—systemic scleroderma	0.000454	0.0153	CbGeAlD
Progesterone—AR—connective tissue—systemic scleroderma	0.000447	0.015	CbGeAlD
Progesterone—ESR1—connective tissue—systemic scleroderma	0.000438	0.0148	CbGeAlD
Progesterone—NR3C2—digestive system—systemic scleroderma	0.000435	0.0147	CbGeAlD
Progesterone—CYP1B1—smooth muscle tissue—systemic scleroderma	0.000431	0.0145	CbGeAlD
Progesterone—CYP1B1—skin of body—systemic scleroderma	0.000426	0.0143	CbGeAlD
Progesterone—NR3C2—tendon—systemic scleroderma	0.000414	0.014	CbGeAlD
Progesterone—AR—smooth muscle tissue—systemic scleroderma	0.000408	0.0138	CbGeAlD
Progesterone—AR—skin of body—systemic scleroderma	0.000403	0.0136	CbGeAlD
Progesterone—ESR1—smooth muscle tissue—systemic scleroderma	0.000401	0.0135	CbGeAlD
Progesterone—CYP2A6—lung—systemic scleroderma	0.000388	0.0131	CbGeAlD
Progesterone—NR3C2—lung—systemic scleroderma	0.000364	0.0123	CbGeAlD
Progesterone—SIGMAR1—tendon—systemic scleroderma	0.000341	0.0115	CbGeAlD
Progesterone—CYP1B1—digestive system—systemic scleroderma	0.000341	0.0115	CbGeAlD
Progesterone—PGR—lung—systemic scleroderma	0.000338	0.0114	CbGeAlD
Progesterone—ABCB1—blood vessel—systemic scleroderma	0.000338	0.0114	CbGeAlD
Progesterone—CYP1B1—tendon—systemic scleroderma	0.000324	0.0109	CbGeAlD
Progesterone—NR3C1—connective tissue—systemic scleroderma	0.000323	0.0109	CbGeAlD
Progesterone—AR—digestive system—systemic scleroderma	0.000322	0.0109	CbGeAlD
Progesterone—ESR1—digestive system—systemic scleroderma	0.000317	0.0107	CbGeAlD
Progesterone—SLC22A3—lung—systemic scleroderma	0.000309	0.0104	CbGeAlD
Progesterone—AR—tendon—systemic scleroderma	0.000307	0.0103	CbGeAlD
Progesterone—CYP1A1—skin of body—systemic scleroderma	0.000301	0.0101	CbGeAlD
Progesterone—SIGMAR1—lung—systemic scleroderma	0.000299	0.0101	CbGeAlD
Progesterone—CYP2C19—digestive system—systemic scleroderma	0.000299	0.0101	CbGeAlD
Progesterone—NR3C1—smooth muscle tissue—systemic scleroderma	0.000296	0.00997	CbGeAlD
Progesterone—NR3C1—skin of body—systemic scleroderma	0.000292	0.00984	CbGeAlD
Progesterone—ABCC1—tendon—systemic scleroderma	0.000291	0.00982	CbGeAlD
Progesterone—CYP1B1—lung—systemic scleroderma	0.000284	0.00958	CbGeAlD
Progesterone—AR—lung—systemic scleroderma	0.000269	0.00908	CbGeAlD
Progesterone—ESR1—lung—systemic scleroderma	0.000264	0.00891	CbGeAlD
Progesterone—ABCC1—lung—systemic scleroderma	0.000256	0.00862	CbGeAlD
Progesterone—CYP1A2—digestive system—systemic scleroderma	0.000244	0.00822	CbGeAlD
Progesterone—CYP1A1—digestive system—systemic scleroderma	0.000241	0.00811	CbGeAlD
Progesterone—CYP3A5—digestive system—systemic scleroderma	0.000235	0.00793	CbGeAlD
Progesterone—NR3C1—digestive system—systemic scleroderma	0.000234	0.00787	CbGeAlD
Progesterone—CYP2C9—digestive system—systemic scleroderma	0.000232	0.00781	CbGeAlD
Progesterone—NR3C1—tendon—systemic scleroderma	0.000222	0.00749	CbGeAlD
Progesterone—CYP1A2—lung—systemic scleroderma	0.000204	0.00687	CbGeAlD
Progesterone—CYP1A1—lung—systemic scleroderma	0.000201	0.00678	CbGeAlD
Progesterone—CYP3A5—lung—systemic scleroderma	0.000197	0.00663	CbGeAlD
Progesterone—NR3C1—lung—systemic scleroderma	0.000195	0.00657	CbGeAlD
Progesterone—CYP3A4—digestive system—systemic scleroderma	0.000177	0.00595	CbGeAlD
Progesterone—CYP2D6—digestive system—systemic scleroderma	0.000174	0.00586	CbGeAlD
Progesterone—ABCB1—digestive system—systemic scleroderma	0.000125	0.00421	CbGeAlD
Progesterone—ABCB1—lung—systemic scleroderma	0.000104	0.00352	CbGeAlD
Progesterone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	8.44e-05	0.00052	CcSEcCtD
Progesterone—Hyperglycaemia—Prednisone—systemic scleroderma	8.43e-05	0.000519	CcSEcCtD
Progesterone—Cough—Mycophenolate mofetil—systemic scleroderma	8.38e-05	0.000516	CcSEcCtD
Progesterone—Hypotension—Lisinopril—systemic scleroderma	8.36e-05	0.000515	CcSEcCtD
Progesterone—Dizziness—Captopril—systemic scleroderma	8.35e-05	0.000514	CcSEcCtD
Progesterone—Liver function test abnormal—Methotrexate—systemic scleroderma	8.34e-05	0.000514	CcSEcCtD
Progesterone—Convulsion—Mycophenolate mofetil—systemic scleroderma	8.32e-05	0.000512	CcSEcCtD
Progesterone—Depression—Prednisone—systemic scleroderma	8.3e-05	0.000512	CcSEcCtD
Progesterone—Hypertension—Mycophenolate mofetil—systemic scleroderma	8.29e-05	0.000511	CcSEcCtD
Progesterone—Urticaria—Leflunomide—systemic scleroderma	8.27e-05	0.000509	CcSEcCtD
Progesterone—Abdominal pain—Leflunomide—systemic scleroderma	8.23e-05	0.000507	CcSEcCtD
Progesterone—Body temperature increased—Leflunomide—systemic scleroderma	8.23e-05	0.000507	CcSEcCtD
Progesterone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	8.18e-05	0.000504	CcSEcCtD
Progesterone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000504	CcSEcCtD
Progesterone—Chest pain—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000504	CcSEcCtD
Progesterone—Myalgia—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000504	CcSEcCtD
Progesterone—Neuropathy peripheral—Prednisone—systemic scleroderma	8.16e-05	0.000503	CcSEcCtD
Progesterone—Breast disorder—Methotrexate—systemic scleroderma	8.16e-05	0.000503	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	8.15e-05	0.000502	CcSEcCtD
Progesterone—Anxiety—Mycophenolate mofetil—systemic scleroderma	8.15e-05	0.000502	CcSEcCtD
Progesterone—Hypersensitivity—Azathioprine—systemic scleroderma	8.12e-05	0.0005	CcSEcCtD
Progesterone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	8.12e-05	0.0005	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	8.12e-05	0.0005	CcSEcCtD
Progesterone—Insomnia—Lisinopril—systemic scleroderma	8.09e-05	0.000498	CcSEcCtD
Progesterone—Discomfort—Mycophenolate mofetil—systemic scleroderma	8.08e-05	0.000497	CcSEcCtD
Progesterone—Paraesthesia—Lisinopril—systemic scleroderma	8.03e-05	0.000495	CcSEcCtD
Progesterone—Vomiting—Captopril—systemic scleroderma	8.03e-05	0.000495	CcSEcCtD
Progesterone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	7.99e-05	0.000492	CcSEcCtD
Progesterone—Dyspnoea—Lisinopril—systemic scleroderma	7.97e-05	0.000491	CcSEcCtD
Progesterone—Rash—Captopril—systemic scleroderma	7.96e-05	0.000491	CcSEcCtD
Progesterone—Dermatitis—Captopril—systemic scleroderma	7.96e-05	0.00049	CcSEcCtD
Progesterone—Somnolence—Lisinopril—systemic scleroderma	7.95e-05	0.00049	CcSEcCtD
Progesterone—Headache—Captopril—systemic scleroderma	7.91e-05	0.000487	CcSEcCtD
Progesterone—Confusional state—Mycophenolate mofetil—systemic scleroderma	7.9e-05	0.000487	CcSEcCtD
Progesterone—Dyspepsia—Lisinopril—systemic scleroderma	7.87e-05	0.000485	CcSEcCtD
Progesterone—Abdominal pain—Mycophenolic acid—systemic scleroderma	7.85e-05	0.000484	CcSEcCtD
Progesterone—Body temperature increased—Mycophenolic acid—systemic scleroderma	7.85e-05	0.000484	CcSEcCtD
Progesterone—Oedema—Mycophenolate mofetil—systemic scleroderma	7.84e-05	0.000483	CcSEcCtD
Progesterone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	7.84e-05	0.000483	CcSEcCtD
Progesterone—Asthma—Methotrexate—systemic scleroderma	7.81e-05	0.000481	CcSEcCtD
Progesterone—Infection—Mycophenolate mofetil—systemic scleroderma	7.78e-05	0.00048	CcSEcCtD
Progesterone—Decreased appetite—Lisinopril—systemic scleroderma	7.77e-05	0.000479	CcSEcCtD
Progesterone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	7.72e-05	0.000476	CcSEcCtD
Progesterone—Fatigue—Lisinopril—systemic scleroderma	7.71e-05	0.000475	CcSEcCtD
Progesterone—Shock—Mycophenolate mofetil—systemic scleroderma	7.71e-05	0.000475	CcSEcCtD
Progesterone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	7.68e-05	0.000473	CcSEcCtD
Progesterone—Hypersensitivity—Leflunomide—systemic scleroderma	7.67e-05	0.000472	CcSEcCtD
Progesterone—Pain—Lisinopril—systemic scleroderma	7.65e-05	0.000471	CcSEcCtD
Progesterone—Constipation—Lisinopril—systemic scleroderma	7.65e-05	0.000471	CcSEcCtD
Progesterone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	7.65e-05	0.000471	CcSEcCtD
Progesterone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	7.61e-05	0.000469	CcSEcCtD
Progesterone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	7.58e-05	0.000467	CcSEcCtD
Progesterone—Diarrhoea—Azathioprine—systemic scleroderma	7.54e-05	0.000465	CcSEcCtD
Progesterone—Haemoglobin—Prednisone—systemic scleroderma	7.51e-05	0.000463	CcSEcCtD
Progesterone—Nausea—Captopril—systemic scleroderma	7.5e-05	0.000462	CcSEcCtD
Progesterone—Abdominal discomfort—Methotrexate—systemic scleroderma	7.48e-05	0.000461	CcSEcCtD
Progesterone—Haemorrhage—Prednisone—systemic scleroderma	7.48e-05	0.000461	CcSEcCtD
Progesterone—Anorexia—Mycophenolate mofetil—systemic scleroderma	7.47e-05	0.00046	CcSEcCtD
Progesterone—Asthenia—Leflunomide—systemic scleroderma	7.47e-05	0.00046	CcSEcCtD
Progesterone—Feeling abnormal—Lisinopril—systemic scleroderma	7.37e-05	0.000454	CcSEcCtD
Progesterone—Pruritus—Leflunomide—systemic scleroderma	7.36e-05	0.000454	CcSEcCtD
Progesterone—Connective tissue disorder—Prednisone—systemic scleroderma	7.35e-05	0.000453	CcSEcCtD
Progesterone—Hypotension—Mycophenolate mofetil—systemic scleroderma	7.32e-05	0.000451	CcSEcCtD
Progesterone—Gastrointestinal pain—Lisinopril—systemic scleroderma	7.31e-05	0.000451	CcSEcCtD
Progesterone—Dysuria—Methotrexate—systemic scleroderma	7.3e-05	0.00045	CcSEcCtD
Progesterone—Dizziness—Azathioprine—systemic scleroderma	7.29e-05	0.000449	CcSEcCtD
Progesterone—Upper respiratory tract infection—Methotrexate—systemic scleroderma	7.26e-05	0.000447	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	7.14e-05	0.00044	CcSEcCtD
Progesterone—Asthenia—Mycophenolic acid—systemic scleroderma	7.12e-05	0.000439	CcSEcCtD
Progesterone—Diarrhoea—Leflunomide—systemic scleroderma	7.12e-05	0.000439	CcSEcCtD
Progesterone—Urticaria—Lisinopril—systemic scleroderma	7.1e-05	0.000438	CcSEcCtD
Progesterone—Insomnia—Mycophenolate mofetil—systemic scleroderma	7.09e-05	0.000437	CcSEcCtD
Progesterone—Abdominal pain—Lisinopril—systemic scleroderma	7.07e-05	0.000436	CcSEcCtD
Progesterone—Body temperature increased—Lisinopril—systemic scleroderma	7.07e-05	0.000436	CcSEcCtD
Progesterone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	7.04e-05	0.000433	CcSEcCtD
Progesterone—Pruritus—Mycophenolic acid—systemic scleroderma	7.03e-05	0.000433	CcSEcCtD
Progesterone—Vomiting—Azathioprine—systemic scleroderma	7.01e-05	0.000432	CcSEcCtD
Progesterone—Pneumonia—Methotrexate—systemic scleroderma	7e-05	0.000431	CcSEcCtD
Progesterone—Eye disorder—Prednisone—systemic scleroderma	6.99e-05	0.00043	CcSEcCtD
Progesterone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	6.99e-05	0.00043	CcSEcCtD
Progesterone—Somnolence—Mycophenolate mofetil—systemic scleroderma	6.97e-05	0.000429	CcSEcCtD
Progesterone—Infestation NOS—Methotrexate—systemic scleroderma	6.96e-05	0.000429	CcSEcCtD
Progesterone—Drowsiness—Methotrexate—systemic scleroderma	6.96e-05	0.000429	CcSEcCtD
Progesterone—Infestation—Methotrexate—systemic scleroderma	6.96e-05	0.000429	CcSEcCtD
Progesterone—Rash—Azathioprine—systemic scleroderma	6.95e-05	0.000428	CcSEcCtD
Progesterone—Dermatitis—Azathioprine—systemic scleroderma	6.94e-05	0.000428	CcSEcCtD
Progesterone—Depression—Methotrexate—systemic scleroderma	6.94e-05	0.000428	CcSEcCtD
Progesterone—Headache—Azathioprine—systemic scleroderma	6.9e-05	0.000425	CcSEcCtD
Progesterone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.9e-05	0.000425	CcSEcCtD
Progesterone—Dizziness—Leflunomide—systemic scleroderma	6.88e-05	0.000424	CcSEcCtD
Progesterone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	6.81e-05	0.00042	CcSEcCtD
Progesterone—Diarrhoea—Mycophenolic acid—systemic scleroderma	6.79e-05	0.000418	CcSEcCtD
Progesterone—Angiopathy—Prednisone—systemic scleroderma	6.78e-05	0.000418	CcSEcCtD
Progesterone—Conjunctivitis—Methotrexate—systemic scleroderma	6.77e-05	0.000417	CcSEcCtD
Progesterone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	6.77e-05	0.000417	CcSEcCtD
Progesterone—Immune system disorder—Prednisone—systemic scleroderma	6.75e-05	0.000416	CcSEcCtD
Progesterone—Constipation—Mycophenolate mofetil—systemic scleroderma	6.7e-05	0.000413	CcSEcCtD
Progesterone—Pain—Mycophenolate mofetil—systemic scleroderma	6.7e-05	0.000413	CcSEcCtD
Progesterone—Vomiting—Leflunomide—systemic scleroderma	6.62e-05	0.000408	CcSEcCtD
Progesterone—Alopecia—Prednisone—systemic scleroderma	6.61e-05	0.000407	CcSEcCtD
Progesterone—Hypersensitivity—Lisinopril—systemic scleroderma	6.59e-05	0.000406	CcSEcCtD
Progesterone—Hepatobiliary disease—Methotrexate—systemic scleroderma	6.58e-05	0.000405	CcSEcCtD
Progesterone—Dizziness—Mycophenolic acid—systemic scleroderma	6.57e-05	0.000404	CcSEcCtD
Progesterone—Rash—Leflunomide—systemic scleroderma	6.56e-05	0.000404	CcSEcCtD
Progesterone—Dermatitis—Leflunomide—systemic scleroderma	6.56e-05	0.000404	CcSEcCtD
Progesterone—Mental disorder—Prednisone—systemic scleroderma	6.55e-05	0.000403	CcSEcCtD
Progesterone—Nausea—Azathioprine—systemic scleroderma	6.55e-05	0.000403	CcSEcCtD
Progesterone—Headache—Leflunomide—systemic scleroderma	6.52e-05	0.000402	CcSEcCtD
Progesterone—Malnutrition—Prednisone—systemic scleroderma	6.51e-05	0.000401	CcSEcCtD
Progesterone—Erythema—Prednisone—systemic scleroderma	6.51e-05	0.000401	CcSEcCtD
Progesterone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	6.46e-05	0.000398	CcSEcCtD
Progesterone—Asthenia—Lisinopril—systemic scleroderma	6.42e-05	0.000395	CcSEcCtD
Progesterone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000395	CcSEcCtD
Progesterone—Pruritus—Lisinopril—systemic scleroderma	6.33e-05	0.00039	CcSEcCtD
Progesterone—Vomiting—Mycophenolic acid—systemic scleroderma	6.31e-05	0.000389	CcSEcCtD
Progesterone—Haemoglobin—Methotrexate—systemic scleroderma	6.28e-05	0.000387	CcSEcCtD
Progesterone—Rash—Mycophenolic acid—systemic scleroderma	6.26e-05	0.000386	CcSEcCtD
Progesterone—Dermatitis—Mycophenolic acid—systemic scleroderma	6.25e-05	0.000385	CcSEcCtD
Progesterone—Hepatitis—Methotrexate—systemic scleroderma	6.25e-05	0.000385	CcSEcCtD
Progesterone—Haemorrhage—Methotrexate—systemic scleroderma	6.25e-05	0.000385	CcSEcCtD
Progesterone—Urticaria—Mycophenolate mofetil—systemic scleroderma	6.23e-05	0.000383	CcSEcCtD
Progesterone—Headache—Mycophenolic acid—systemic scleroderma	6.22e-05	0.000383	CcSEcCtD
Progesterone—Pharyngitis—Methotrexate—systemic scleroderma	6.2e-05	0.000382	CcSEcCtD
Progesterone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000382	CcSEcCtD
Progesterone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	6.19e-05	0.000382	CcSEcCtD
Progesterone—Nausea—Leflunomide—systemic scleroderma	6.18e-05	0.000381	CcSEcCtD
Progesterone—Urinary tract disorder—Methotrexate—systemic scleroderma	6.17e-05	0.00038	CcSEcCtD
Progesterone—Vision blurred—Prednisone—systemic scleroderma	6.13e-05	0.000378	CcSEcCtD
Progesterone—Urethral disorder—Methotrexate—systemic scleroderma	6.12e-05	0.000377	CcSEcCtD
Progesterone—Diarrhoea—Lisinopril—systemic scleroderma	6.12e-05	0.000377	CcSEcCtD
Progesterone—Ill-defined disorder—Prednisone—systemic scleroderma	6.04e-05	0.000372	CcSEcCtD
Progesterone—Visual impairment—Methotrexate—systemic scleroderma	6.02e-05	0.000371	CcSEcCtD
Progesterone—Anaemia—Prednisone—systemic scleroderma	6.02e-05	0.000371	CcSEcCtD
Progesterone—Angioedema—Prednisone—systemic scleroderma	5.95e-05	0.000366	CcSEcCtD
Progesterone—Dizziness—Lisinopril—systemic scleroderma	5.91e-05	0.000364	CcSEcCtD
Progesterone—Erythema multiforme—Methotrexate—systemic scleroderma	5.91e-05	0.000364	CcSEcCtD
Progesterone—Nausea—Mycophenolic acid—systemic scleroderma	5.9e-05	0.000363	CcSEcCtD
Progesterone—Malaise—Prednisone—systemic scleroderma	5.87e-05	0.000362	CcSEcCtD
Progesterone—Vertigo—Prednisone—systemic scleroderma	5.85e-05	0.00036	CcSEcCtD
Progesterone—Eye disorder—Methotrexate—systemic scleroderma	5.84e-05	0.00036	CcSEcCtD
Progesterone—Syncope—Prednisone—systemic scleroderma	5.84e-05	0.00036	CcSEcCtD
Progesterone—Tinnitus—Methotrexate—systemic scleroderma	5.83e-05	0.000359	CcSEcCtD
Progesterone—Cardiac disorder—Methotrexate—systemic scleroderma	5.8e-05	0.000357	CcSEcCtD
Progesterone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.77e-05	0.000356	CcSEcCtD
Progesterone—Loss of consciousness—Prednisone—systemic scleroderma	5.72e-05	0.000352	CcSEcCtD
Progesterone—Vomiting—Lisinopril—systemic scleroderma	5.69e-05	0.00035	CcSEcCtD
Progesterone—Angiopathy—Methotrexate—systemic scleroderma	5.67e-05	0.000349	CcSEcCtD
Progesterone—Immune system disorder—Methotrexate—systemic scleroderma	5.64e-05	0.000348	CcSEcCtD
Progesterone—Rash—Lisinopril—systemic scleroderma	5.64e-05	0.000347	CcSEcCtD
Progesterone—Convulsion—Prednisone—systemic scleroderma	5.64e-05	0.000347	CcSEcCtD
Progesterone—Dermatitis—Lisinopril—systemic scleroderma	5.63e-05	0.000347	CcSEcCtD
Progesterone—Mediastinal disorder—Methotrexate—systemic scleroderma	5.63e-05	0.000347	CcSEcCtD
Progesterone—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.62e-05	0.000346	CcSEcCtD
Progesterone—Hypertension—Prednisone—systemic scleroderma	5.62e-05	0.000346	CcSEcCtD
Progesterone—Headache—Lisinopril—systemic scleroderma	5.6e-05	0.000345	CcSEcCtD
Progesterone—Pruritus—Mycophenolate mofetil—systemic scleroderma	5.54e-05	0.000342	CcSEcCtD
Progesterone—Myalgia—Prednisone—systemic scleroderma	5.54e-05	0.000341	CcSEcCtD
Progesterone—Arthralgia—Prednisone—systemic scleroderma	5.54e-05	0.000341	CcSEcCtD
Progesterone—Anxiety—Prednisone—systemic scleroderma	5.52e-05	0.00034	CcSEcCtD
Progesterone—Alopecia—Methotrexate—systemic scleroderma	5.52e-05	0.00034	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	5.5e-05	0.000339	CcSEcCtD
Progesterone—Discomfort—Prednisone—systemic scleroderma	5.47e-05	0.000337	CcSEcCtD
Progesterone—Mental disorder—Methotrexate—systemic scleroderma	5.47e-05	0.000337	CcSEcCtD
Progesterone—Malnutrition—Methotrexate—systemic scleroderma	5.44e-05	0.000335	CcSEcCtD
Progesterone—Erythema—Methotrexate—systemic scleroderma	5.44e-05	0.000335	CcSEcCtD
Progesterone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	5.36e-05	0.00033	CcSEcCtD
Progesterone—Nausea—Lisinopril—systemic scleroderma	5.31e-05	0.000327	CcSEcCtD
Progesterone—Anaphylactic shock—Prednisone—systemic scleroderma	5.31e-05	0.000327	CcSEcCtD
Progesterone—Oedema—Prednisone—systemic scleroderma	5.31e-05	0.000327	CcSEcCtD
Progesterone—Infection—Prednisone—systemic scleroderma	5.28e-05	0.000325	CcSEcCtD
Progesterone—Back pain—Methotrexate—systemic scleroderma	5.26e-05	0.000324	CcSEcCtD
Progesterone—Shock—Prednisone—systemic scleroderma	5.23e-05	0.000322	CcSEcCtD
Progesterone—Nervous system disorder—Prednisone—systemic scleroderma	5.21e-05	0.000321	CcSEcCtD
Progesterone—Tachycardia—Prednisone—systemic scleroderma	5.18e-05	0.000319	CcSEcCtD
Progesterone—Dizziness—Mycophenolate mofetil—systemic scleroderma	5.18e-05	0.000319	CcSEcCtD
Progesterone—Skin disorder—Prednisone—systemic scleroderma	5.16e-05	0.000318	CcSEcCtD
Progesterone—Hyperhidrosis—Prednisone—systemic scleroderma	5.13e-05	0.000316	CcSEcCtD
Progesterone—Vision blurred—Methotrexate—systemic scleroderma	5.13e-05	0.000316	CcSEcCtD
Progesterone—Anorexia—Prednisone—systemic scleroderma	5.06e-05	0.000312	CcSEcCtD
Progesterone—Ill-defined disorder—Methotrexate—systemic scleroderma	5.05e-05	0.000311	CcSEcCtD
Progesterone—Anaemia—Methotrexate—systemic scleroderma	5.03e-05	0.00031	CcSEcCtD
Progesterone—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.98e-05	0.000307	CcSEcCtD
Progesterone—Rash—Mycophenolate mofetil—systemic scleroderma	4.94e-05	0.000304	CcSEcCtD
Progesterone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.94e-05	0.000304	CcSEcCtD
Progesterone—Headache—Mycophenolate mofetil—systemic scleroderma	4.91e-05	0.000302	CcSEcCtD
Progesterone—Malaise—Methotrexate—systemic scleroderma	4.91e-05	0.000302	CcSEcCtD
Progesterone—Vertigo—Methotrexate—systemic scleroderma	4.89e-05	0.000301	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	4.84e-05	0.000298	CcSEcCtD
Progesterone—Insomnia—Prednisone—systemic scleroderma	4.8e-05	0.000296	CcSEcCtD
Progesterone—Paraesthesia—Prednisone—systemic scleroderma	4.77e-05	0.000294	CcSEcCtD
Progesterone—Cough—Methotrexate—systemic scleroderma	4.75e-05	0.000292	CcSEcCtD
Progesterone—Convulsion—Methotrexate—systemic scleroderma	4.71e-05	0.00029	CcSEcCtD
Progesterone—Dyspepsia—Prednisone—systemic scleroderma	4.68e-05	0.000288	CcSEcCtD
Progesterone—Nausea—Mycophenolate mofetil—systemic scleroderma	4.65e-05	0.000287	CcSEcCtD
Progesterone—Myalgia—Methotrexate—systemic scleroderma	4.63e-05	0.000285	CcSEcCtD
Progesterone—Chest pain—Methotrexate—systemic scleroderma	4.63e-05	0.000285	CcSEcCtD
Progesterone—Arthralgia—Methotrexate—systemic scleroderma	4.63e-05	0.000285	CcSEcCtD
Progesterone—Decreased appetite—Prednisone—systemic scleroderma	4.62e-05	0.000284	CcSEcCtD
Progesterone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	4.6e-05	0.000283	CcSEcCtD
Progesterone—Fatigue—Prednisone—systemic scleroderma	4.58e-05	0.000282	CcSEcCtD
Progesterone—Discomfort—Methotrexate—systemic scleroderma	4.58e-05	0.000282	CcSEcCtD
Progesterone—Constipation—Prednisone—systemic scleroderma	4.54e-05	0.00028	CcSEcCtD
Progesterone—Confusional state—Methotrexate—systemic scleroderma	4.48e-05	0.000276	CcSEcCtD
Progesterone—Anaphylactic shock—Methotrexate—systemic scleroderma	4.44e-05	0.000273	CcSEcCtD
Progesterone—Infection—Methotrexate—systemic scleroderma	4.41e-05	0.000272	CcSEcCtD
Progesterone—Feeling abnormal—Prednisone—systemic scleroderma	4.38e-05	0.00027	CcSEcCtD
Progesterone—Nervous system disorder—Methotrexate—systemic scleroderma	4.35e-05	0.000268	CcSEcCtD
Progesterone—Gastrointestinal pain—Prednisone—systemic scleroderma	4.34e-05	0.000268	CcSEcCtD
Progesterone—Skin disorder—Methotrexate—systemic scleroderma	4.31e-05	0.000266	CcSEcCtD
Progesterone—Hyperhidrosis—Methotrexate—systemic scleroderma	4.29e-05	0.000264	CcSEcCtD
Progesterone—Anorexia—Methotrexate—systemic scleroderma	4.23e-05	0.000261	CcSEcCtD
Progesterone—Urticaria—Prednisone—systemic scleroderma	4.22e-05	0.00026	CcSEcCtD
Progesterone—Abdominal pain—Prednisone—systemic scleroderma	4.2e-05	0.000259	CcSEcCtD
Progesterone—Body temperature increased—Prednisone—systemic scleroderma	4.2e-05	0.000259	CcSEcCtD
Progesterone—Hypotension—Methotrexate—systemic scleroderma	4.15e-05	0.000256	CcSEcCtD
Progesterone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.04e-05	0.000249	CcSEcCtD
Progesterone—Insomnia—Methotrexate—systemic scleroderma	4.02e-05	0.000247	CcSEcCtD
Progesterone—Paraesthesia—Methotrexate—systemic scleroderma	3.99e-05	0.000246	CcSEcCtD
Progesterone—Dyspnoea—Methotrexate—systemic scleroderma	3.96e-05	0.000244	CcSEcCtD
Progesterone—Somnolence—Methotrexate—systemic scleroderma	3.95e-05	0.000243	CcSEcCtD
Progesterone—Hypersensitivity—Prednisone—systemic scleroderma	3.91e-05	0.000241	CcSEcCtD
Progesterone—Dyspepsia—Methotrexate—systemic scleroderma	3.91e-05	0.000241	CcSEcCtD
Progesterone—Decreased appetite—Methotrexate—systemic scleroderma	3.86e-05	0.000238	CcSEcCtD
Progesterone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.83e-05	0.000236	CcSEcCtD
Progesterone—Fatigue—Methotrexate—systemic scleroderma	3.83e-05	0.000236	CcSEcCtD
Progesterone—Asthenia—Prednisone—systemic scleroderma	3.81e-05	0.000235	CcSEcCtD
Progesterone—Pain—Methotrexate—systemic scleroderma	3.8e-05	0.000234	CcSEcCtD
Progesterone—Pruritus—Prednisone—systemic scleroderma	3.76e-05	0.000231	CcSEcCtD
Progesterone—Feeling abnormal—Methotrexate—systemic scleroderma	3.66e-05	0.000225	CcSEcCtD
Progesterone—Diarrhoea—Prednisone—systemic scleroderma	3.63e-05	0.000224	CcSEcCtD
Progesterone—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.63e-05	0.000224	CcSEcCtD
Progesterone—Urticaria—Methotrexate—systemic scleroderma	3.53e-05	0.000217	CcSEcCtD
Progesterone—Dizziness—Prednisone—systemic scleroderma	3.51e-05	0.000216	CcSEcCtD
Progesterone—Abdominal pain—Methotrexate—systemic scleroderma	3.51e-05	0.000216	CcSEcCtD
Progesterone—Body temperature increased—Methotrexate—systemic scleroderma	3.51e-05	0.000216	CcSEcCtD
Progesterone—Vomiting—Prednisone—systemic scleroderma	3.38e-05	0.000208	CcSEcCtD
Progesterone—Rash—Prednisone—systemic scleroderma	3.35e-05	0.000206	CcSEcCtD
Progesterone—Dermatitis—Prednisone—systemic scleroderma	3.35e-05	0.000206	CcSEcCtD
Progesterone—Headache—Prednisone—systemic scleroderma	3.33e-05	0.000205	CcSEcCtD
Progesterone—Hypersensitivity—Methotrexate—systemic scleroderma	3.27e-05	0.000201	CcSEcCtD
Progesterone—Asthenia—Methotrexate—systemic scleroderma	3.19e-05	0.000196	CcSEcCtD
Progesterone—Nausea—Prednisone—systemic scleroderma	3.16e-05	0.000194	CcSEcCtD
Progesterone—Pruritus—Methotrexate—systemic scleroderma	3.14e-05	0.000193	CcSEcCtD
Progesterone—Diarrhoea—Methotrexate—systemic scleroderma	3.04e-05	0.000187	CcSEcCtD
Progesterone—Dizziness—Methotrexate—systemic scleroderma	2.94e-05	0.000181	CcSEcCtD
Progesterone—Vomiting—Methotrexate—systemic scleroderma	2.82e-05	0.000174	CcSEcCtD
Progesterone—Rash—Methotrexate—systemic scleroderma	2.8e-05	0.000172	CcSEcCtD
Progesterone—Dermatitis—Methotrexate—systemic scleroderma	2.8e-05	0.000172	CcSEcCtD
Progesterone—Headache—Methotrexate—systemic scleroderma	2.78e-05	0.000171	CcSEcCtD
Progesterone—Nausea—Methotrexate—systemic scleroderma	2.64e-05	0.000162	CcSEcCtD
